- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
The dark side of immunotherapy
Emiliano Calvo
Start Madrid, Madrid, Spain
- Free
- slides video
- audio + slides
- All slides included
Inhibitors of the HSF1 stress pathway derived from phenotypic screening: Targeting non-oncogene addiction in ovarian and other cancers
Paul Workman
The Institute of Cancer Research, London, United Kingdom
- Free
- podium video
- audio + slides
- Some slides withheld
Early lessons from initial acquired resistance to TRK inhibitors
David M Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Mechanisms of resistance to tumor-specific vaccination: Beyond PD-1 blockade
Douglas G. McNeel
University of Wisconsin, Madison, WI, United States
- Permission not
granted for presentation
Identification of genes and pathways of immune resistance to IO via analysis of neoadjuvant treatment with anti-PD-1
Drew M Pardoll
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
- Permission not
granted for presentation
Discovery of BI-3406: a potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors
Marco H Hofmann
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
- Free
- slides video
- audio + slides
- All slides included
ALK2 open drug discovery: A development path from genes to affordable medicines in DIPG
Aled Edwards
Structural Genomics Consortium, Toronto, ON, Canada
- Free
- slides video
- audio + slides
- All slides included
Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
Geraldine O'Sullivan Coyne
National Cancer Institute, Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
Alan Ho
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Permission not
granted for presentation
Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors
Anthony W. Tolcher
NEXT Oncology, San Antonio, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo
Christopher J Schulze
Revolution Medicines, Redwood City, CA, United States
- Free
- slides video
- audio + slides
- All slides included
Antibody Drug Conjugates in solid tumors: The model of breast cancer
Giuseppe Curigliano
University of Milan, Milan, Italy
- Permission not
granted for presentation
Immunotoxins targeting GPC3 for liver cancer
Mitchell Ho
National Cancer Institute, Bethesda, MD, United States
- Free
- audio + slides
- Some slides withheld
Recombinant immunotoxins for hematologic malignancies
Robert Kreitman
National Cancer Institute, Bethesda, MD, United States
- Permission not
granted for presentation
IL-8 in tumor progression
Claudia Palena
National Cancer Institute, Bethesda, MD, United States
- Permission not
granted for presentation
BMP signaling in glioblastoma
Kohei Miyazono
University of Tokyo, Tokyo, Japan
- Free
- slides video
- audio + slides
- All slides included
LIF in cancer
Joan Seoane
Vall d’Hebron Institute of Oncology, Barcelona, Spain
- Free
- slides video
- audio + slides
- All slides included
Lessons learnt in clinic from resistance to first generation molecular targeted therapies in solid cancers
Ahmad Awada
Jules Bordet Institute, Brussels, Belgium
- Permission not
granted for presentation
Spatially resolved profiling of the tumor-immune microenvironment during neoadjuvant HER2-targeted therapy predicts response
Christina Curtis
Stanford University, Stanford, CA, United States